| Wall Street Journal. Europe 2001 Geeta Anand |
| Title | Subject | Authors |
|---|
| A fight starts for custom drugs.(Pharmaceutical companies resist personalized treatments for fear they may hurt sales.) | Business, international | Geeta Anand |
| Amgen discusses acquisition of Immunex for $17 billion. | Business, international | David P. Hamilton, Robin Sidel, Geeta Anand |
| Lilly, Bayer drugs will tackle Viagra.(Cialis and Vardenafil may act faster, have fewer side effects than Pfizer medication.) | Business, international | Thomas M. Burton, Geeta Anand |
| Merck, Schering-Plough, AHP suffer setbacks, and stocks fall.(Slump shows problem with relying on blockbuster drugs.) | Business, international | Gardiner Harris, Geeta Anand |
| Roche unit in pact to develop tools for gene research.(CombiMatrix deal may reach Euro591 million in sales.) | Business, international | Geeta Anand |
| Small firms may play big role in U.S. stockpile of vaccines; Therion, Novavax ready to respond to threat of smallpox outbreak.(getting ready for bioterrorism) | Business, international | Geeta Anand |
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
